Schedule 13G ownership disclosure

CytomX Therapeutics Inc

Common Stock, $0.00001 par value per share · CUSIP: 23284F105

Event date: 2025-07-03

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BIOTECHNOLOGY VALUE FUND L P

    Shares: 3,074,013.00 · Class: 1.9%

  • BVF I GP LLC

    Shares: 3,074,013.00 · Class: 1.9%

  • BIOTECHNOLOGY VALUE FUND II LP

    Shares: 2,351,446.00 · Class: 1.5%

  • BVF II GP LLC

    Shares: 2,351,446.00 · Class: 1.5%

  • Biotechnology Value Trading Fund OS LP

    Shares: 270,616.00 · Class: 0.2%

  • BVF Partners OS Ltd.

    Shares: 270,616.00 · Class: 0.2%

  • BVF GP HOLDINGS LLC

    Shares: 5,425,459.00 · Class: 3.3%

  • BVF PARTNERS L P/IL

    Shares: 5,769,231.00 · Class: 3.5%

  • BVF INC/IL

    Shares: 5,769,231.00 · Class: 3.5%

  • LAMPERT MARK N

    Shares: 5,769,231.00 · Class: 3.5%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-25-001982
Form type
SCHEDULE 13G/A
Filer
BIOTECHNOLOGY VALUE FUND L P
CIK
CIK 918923
Filed
Jul 09, 2025
Reporting period
Jul 03, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub